World Rural Health Conference
Home Print this page Email this page Small font size Default font size Increase font size
Users Online: 1015
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 


 
 Table of Contents 
LETTER TO EDITOR
Year : 2016  |  Volume : 5  |  Issue : 3  |  Page : 736-737  

Aripiprazole cardiosafety: Is it overestimated?


Al-Manara CAP Centre, Kuwait Centre for Mental Health, Shuwaikh, Kuwait

Date of Web Publication30-Dec-2016

Correspondence Address:
Ahmed Naguy
Al Manara CAP Centre, Kuwait Centre for Mental Health, Jamal Abdul Nassir Street, Shuwaikh
Kuwait
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2249-4863.197283

Rights and Permissions

How to cite this article:
Naguy A. Aripiprazole cardiosafety: Is it overestimated?. J Family Med Prim Care 2016;5:736-7

How to cite this URL:
Naguy A. Aripiprazole cardiosafety: Is it overestimated?. J Family Med Prim Care [serial online] 2016 [cited 2019 Aug 18];5:736-7. Available from: http://www.jfmpc.com/text.asp?2016/5/3/736/197283

Aripiprazole is a third-generation atypical (novel) antipsychotic, dihydroquinolinone, famously known as dopamine stabilizer, uniquely D2/D3 partial agonist, and 5HT1A agonist. It is a Food and Drug Administration-approved drug for schizophrenia, bipolar mood disorder, augmentation in unipolar depression, irritability in autism, and Tourette syndrome in pediatric age group. It is lauded for being cardiometabolic-friendly, [1] in stark contradistinction to most atypical antipsychotics currently on the market. Nelson and Leung [2] recently reported unusual QTc prolongation associated with aripiprazole use. Similarly, Hategan and Bourgeois [3] reported aripiprazole-associated QTc prolongation in a geriatric patient. Lam, [4] too, noted QTc prolongation associated with aripiprazole. Suzuki et al. [5] reported a dose-dependent of QTc interval at 30 mg of aripiprazole. Egger et al. [6] reported a case of dose-dependent aripiprazole-induced conduction disturbance. Torgovnick et al. [7] reported on aripiprazole-induced orthostatic hypotension and supraventricular tachyarrhythmia. Shao et al. [8] reported a case of ventricular trigeminy induced by overdose aripiprazole.

Here, I report on three cases where aripiprazole was associated with cardiac adversities.

Case 1: A 15-year-old female, bipolar I disorder, overweight, baseline electrocardiogram (ECG) and metabolic (Met) screen unrevealing, no history of cardiac comorbidities, was put to 45 mg aripiprazole monotherapy. She developed asymptomatic first-degree AV block that reversed on decreasing dose back to 30 mg/day within days. With rechallenging at 45 mg dosing, PR interval lengthened again at 22 ms. Naranjo Adverse Drug Reaction Probability Scale scored 7.

Case 2: A 48-year-old female, perimenopausal, schizoaffective disorder, bipolar subtype, baseline ECG and Met screen with negative yield, no vascular risks, no history of cardiac comorbidities, was maintained on risperidone 4 mg/day. She developed asymptomatic hyperprolactinemia. Aripiprazole 3 mg was added to mitigate hyperprolactinemia. Follow-up ECG read left bundle branch block. Aripiprazole was discontinued. ECG morphed into tachy-dependent anteroseptal subepicardial ischemia, and then normalized over a course of 2 weeks. Naranjo scale scored 3.

Case 3: A 32-year-old male, bipolar I disorder, manic, baseline ECG and Met screen unrevealing, no history of cardiac comorbidities, nonsmoker, was put to 30 mg aripiprazole with 2 mg clonazepam. ECG read right bundle branch block. He was shifted to olanzapine and ECG normalized shortly after. Naranjo scale scored 6.

These reports remain scattered. Nonetheless, it cast some doubt that aripiprazole cardiosafety taken at face value might be overstated. Hence, caution should be exercised while prescribing aripiprazole, especially for high-risk groups and cardiac monitoring might then be warranted.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

 
  References Top

1.
Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, et al. Aripiprazole in the treatment of schizophrenia: Safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003;61:123-36.  Back to cited text no. 1
    
2.
Nelson S, Leung JG. Torsades de pointes after administration of low-dose aripiprazole. Ann Pharmacother 2013;47:e11.  Back to cited text no. 2
    
3.
Hategan A, Bourgeois JA. Aripiprazole-associated QTc prolongation in a geriatric patient. J Clin Psychopharmacol 2014;34:766-8.  Back to cited text no. 3
    
4.
Lam YM. QTc prolongation associated with aripiprazole. Brown Univ Psychopharmacol Update 2015;26:2-3.  Back to cited text no. 4
    
5.
Suzuki Y, Ono S, Fukui N, Sugai T, Watanabe J, Tsuneyama N, et al. Dose-dependent increase in the QTc interval in aripiprazole treatment after risperidone. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:643-4.  Back to cited text no. 5
    
6.
Egger C, Rauscher A, Muehlbacher M, Nickel M, Geretsegger C, Stuppaeck C. A case of dose-dependent aripiprazole-induced conduction disturbance. J Clin Psychopharmacol 2006;26:436.  Back to cited text no. 6
    
7.
Torgovnick J, Sethi NK, Arsura E. Aripiprazole-induced orthostatic hypotension and cardiac arrhythmia. Psychiatry Clin Neurosci 2008;62:485.  Back to cited text no. 7
    
8.
Shao Q, Quan W, Jia X, Chen J, Ma S, Zhang X. Severe arrhythmia induced by orally disintegrating aripiprazole tablets (Bosiqing(®)): A case report. Neuropsychiatr Dis Treat 2015;11:3019-21.  Back to cited text no. 8
    




 

Top
   
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

 
  In this article
   References

 Article Access Statistics
    Viewed742    
    Printed7    
    Emailed0    
    PDF Downloaded72    
    Comments [Add]    

Recommend this journal